Stock listing
Munich:27F Kala Bio, Inc. Aktie
German listing (Munich) of Kala Bio, Inc. · home listing NASDAQ:KALA
Follow Kala Bio, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:KALA
$2.71 USD -0.55 (-17.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:KALA
- Day range
- $2.65 – $3.17 USDNov 20, 2026
- Volume
- 18,551 sharesNov 20, 2026
- Market cap
- $1.74M USDAt the close on Nov 20, 2026 · price × 644,660 shares outstanding
- 52-week range
- $2.65 – $2,865.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $26,651 USDMedian day 273 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KALA · Home | $2.705 USD | -0.555 (-17.0%) | 18,551 | $3.02 | $3.17 | $2.65 | $3.26 | Close on Nov 20, 2026 |
| LSE:0JQ2 | $2.90 USD | -0.33 (-10.2%) | 651 | $3.30 | $3.30 | $2.87 | $3.23 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KALA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.705 | -0.555 | -17.0% | $3.02 | $3.17 | $2.65 | 18,551 | |
| $3.26 | -0.17 | -5.0% | $3.72 | $3.72 | $3.26 | 7,946 | |
| $3.43 | -0.40 | -10.4% | $3.50 | $3.70 | $3.42 | 11,882 | |
| $3.83 | -0.334 | -8.0% | $3.79 | $4.033 | $3.51 | 29,804 | |
| $4.164 | -0.666 | -13.8% | $4.488 | $4.53 | $3.96 | 1,041 | |
| $4.83 | -0.30 | -5.8% | $5.01 | $5.118 | $4.761 | 428 | |
| $5.13 | 0.00 | 0.0% | $5.16 | $5.22 | $4.98 | 117 | |
| $5.13 | -0.189 | -3.6% | $5.19 | $5.538 | $5.067 | 159 | |
| $5.319 | +0.642 | +13.7% | $4.839 | $5.337 | $4.839 | 239 | |
| $4.677 | +0.102 | +2.2% | $5.10 | $5.10 | $4.536 | 160 | |
| $4.575 | -0.768 | -14.4% | $5.55 | $5.55 | $4.50 | 257 | |
| $5.343 | +0.153 | +2.9% | $5.397 | $5.556 | $5.163 | 91 | |
| $5.19 | +0.174 | +3.5% | $4.998 | $5.544 | $4.989 | 237 | |
| $5.016 | +0.051 | +1.0% | $5.10 | $5.397 | $4.989 | 171 | |
| $4.965 | -0.288 | -5.5% | $5.25 | $5.496 | $4.89 | 273 | |
| $5.253 | -0.144 | -2.7% | $5.598 | $5.691 | $5.25 | 191 | |
| $5.397 | +0.123 | +2.3% | $5.40 | $5.64 | $5.25 | 122 | |
| $5.274 | -0.312 | -5.6% | $5.46 | $5.634 | $5.133 | 210 | |
| $5.586 | -0.117 | -2.1% | $5.70 | $5.82 | $5.49 | 132 | |
| $5.703 | +0.138 | +2.5% | $5.586 | $6.00 | $5.553 | 231 | |
| $5.565 | -0.159 | -2.8% | $5.73 | $5.898 | $5.463 | 134 | |
| $5.724 | +0.033 | +0.6% | $6.03 | $6.153 | $5.463 | 262 | |
| $5.691 | -0.087 | -1.5% | $5.94 | $6.30 | $5.574 | 417 | |
| $5.778 | +0.081 | +1.4% | $6.00 | $6.30 | $5.70 | 282 | |
| $5.697 | -0.069 | -1.2% | $5.97 | $5.991 | $5.463 | 320 | |
| $5.766 | +0.126 | +2.2% | $5.709 | $6.153 | $5.16 | 956 | |
| $5.64 | -2.16 | -27.7% | $7.791 | $7.938 | $3.438 | 1,853 | |
| $7.80 | -0.60 | -7.1% | $8.55 | $8.55 | $7.779 | 474 | |
| $8.40 | -0.42 | -4.8% | $8.553 | $8.94 | $8.322 | 423 | |
| $8.82 | -0.078 | -0.9% | $9.048 | $9.048 | $8.58 | 317 | |
| $8.898 | -1.902 | -17.6% | $10.44 | $10.48 | $8.745 | 736 | |
| $10.80 | -0.12 | -1.1% | $11.19 | $11.85 | $10.28 | 727 | |
| $10.92 | +0.045 | +0.4% | $10.50 | $11.70 | $10.32 | 467 | |
| $10.88 | -0.675 | -5.8% | $11.61 | $11.70 | $10.53 | 1,202 | |
| $11.55 | -1.032 | -8.2% | $12.30 | $12.60 | $11.41 | 1,195 | |
| $12.58 | -0.297 | -2.3% | $12.50 | $13.76 | $12.24 | 1,802 | |
| $12.88 | -2.22 | -14.7% | $15.76 | $16.14 | $12.31 | 32,704 | |
| $15.10 | +1.593 | +11.8% | $12.43 | $16.20 | $12.03 | 42,143 | |
| $13.51 | -0.762 | -5.3% | $13.91 | $14.69 | $12.94 | 641 | |
| $14.27 | -2.532 | -15.1% | $16.38 | $16.50 | $13.94 | 405 | |
| $16.80 | 0.00 | 0.0% | $15.93 | $17.10 | $15.75 | 771 | |
| $16.80 | -1.17 | -6.5% | $17.45 | $17.71 | $16.80 | 92 | |
| $17.97 | +1.17 | +7.0% | $17.10 | $18.35 | $16.51 | 152 | |
| $16.80 | +0.63 | +3.9% | $16.98 | $17.39 | $16.30 | 57 | |
| $16.17 | -0.768 | -4.5% | $16.49 | $17.40 | $15.93 | 91 | |
| $16.94 | +1.29 | +8.2% | $16.77 | $17.31 | $16.04 | 138 | |
| $15.65 | +0.417 | +2.7% | $16.05 | $16.21 | $15.33 | 194 | |
| $15.23 | -0.99 | -6.1% | $16.40 | $16.60 | $15.01 | 201 | |
| $16.22 | -0.951 | -5.5% | $17.40 | $17.50 | $16.06 | 203 | |
| $17.17 | +0.285 | +1.7% | $17.76 | $17.99 | $17.17 | 124 | |
| $16.89 | +0.186 | +1.1% | $16.80 | $18.06 | $16.51 | 344 | |
| $16.70 | +0.564 | +3.5% | $16.01 | $18.30 | $15.87 | 594 | |
| $16.14 | +0.918 | +6.0% | $15.60 | $16.39 | $14.70 | 195 | |
| $15.22 | -1.611 | -9.6% | $16.35 | $16.71 | $15.02 | 290 | |
| $16.83 | +1.155 | +7.4% | $15.81 | $17.25 | $15.60 | 642 | |
| $15.67 | -0.291 | -1.8% | $16.05 | $16.96 | $15.09 | 490 | |
| $15.97 | -4.215 | -20.9% | $15.62 | $17.10 | $15.30 | 10,083 | |
| $20.18 | -0.522 | -2.5% | $20.36 | $22.80 | $19.89 | 267 | |
| $20.70 | -3.66 | -15.0% | $24.99 | $32.79 | $17.60 | 2,685 | |
| $24.36 | -0.12 | -0.5% | $24.03 | $25.50 | $24.03 | 36 | |
| $24.48 | -0.147 | -0.6% | $24.30 | $24.79 | $24.30 | 68 | |
| $24.63 | +0.768 | +3.2% | $25.20 | $25.20 | $23.70 | 24 | |
| $23.86 | -0.741 | -3.0% | $24.60 | $25.20 | $23.45 | 63 | |
| $24.60 | -0.60 | -2.4% | $29.52 | $29.52 | $24.00 | 112 | |
| $25.20 | -1.797 | -6.7% | $28.17 | $28.76 | $24.30 | 72 |
Splits
3 splits since 2022 · NASDAQ:KALA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation | |
| 1-for-50 | Consolidation | |
| 1-for-50 | Consolidation |
- Ticker
- Munich:27F
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
KALA BIO Announces Reverse Stock Split
Latest news
KALA BIO Announces Reverse Stock Split
Nov 12, 2026
Closed $4.83 (-5.8%) on Nov 12, 2026
KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results
Nov 9, 2026
Closed $5.32 (+13.7%) on Nov 9, 2026
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Sep 29, 2026
Closed $15.10 (+11.8%) on Sep 29, 2026
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
Sep 17, 2026
Closed $16.94 (+8.2%) on Sep 17, 2026
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Sep 3, 2026
Closed $16.83 (+7.4%) on Sep 3, 2026
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Sep 1, 2026
Closed $15.97 (-20.9%) on Sep 1, 2026
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
Apr 21, 2026
Closed $277.65 (-7.5%) on Apr 21, 2026
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Apr 1, 2026
Closed $244.50 (-5.8%) on Apr 1, 2026
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Mar 30, 2026
Closed $256.50 (-2.7%) on Mar 30, 2026
Kala Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 114 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 7 calls with a replay · 7 with a transcript · latest Aug 11, 2022
Where Kala Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KALA · Home listing | NASDAQ | United States | USD |
| gettex:27F0 | gettex | Germany | EUR |
| LS Exchange:A3DWPS | LS Exchange | Germany | EUR |
| BOATS:KALA | BOATS | United States | USD |
| LSE:0JQ2 | LSE | United Kingdom | USD |
| Lang & Schwarz:A3DWPS | Lang & Schwarz | Germany | EUR |
| Tradegate:27F | Tradegate | Germany | EUR |
| gettex:27F | gettex | Germany | EUR |
| Munich:27F · This page | Munich | Germany | EUR |
| LS Exchange:A4243T | LS Exchange | Germany | EUR |
| Frankfurt:27F | Frankfurt | Germany | EUR |
| Lang & Schwarz:A4243T | Lang & Schwarz | Germany | EUR |
Valuation
Price/book 0.2× against a median of 0.4×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$5.49M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.76
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kala Bio, Inc. · NASDAQ:KALA | US$1.74M | −US$5.49M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 2.76 |
| CASI Pharmaceuticals, Inc. · OTC:CASIF | US$2.06M | US$38.79M | n/a | 1.9× | n/a | n/a | −218.6% | n/a | -0.07 |
| Vectus Biosystems Limited · ASX:VBS | US$2.02M | US$50,966 | 1.9× | n/a | n/a | 1.3× | n/a | 0.2× | n/a |
| Decoy Therapeutics Inc. · NASDAQ:DCOY | US$1.98M | −US$6.19M | n/a | −11.6× | n/a | 0.4× | n/a | 0.0× | 1.28 |
| Genprex, Inc. · NASDAQ:GNPX | US$1.94M | −US$13.41M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.08 |
| Propanc Biopharma, Inc. · NASDAQ:PPCB | US$1.84M | US$1.62M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.39 |
| Argent Biopharma Ltd · ASX:RGT | US$1.79M | US$8.05M | n/a | 75.4× | n/a | n/a | n/a | n/a | n/a |
| Calidi Biotherapeutics, Inc. · AMEX:CLDI | US$1.76M | −US$2.19M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.86 |
| SOHM, Inc. · OTC:SHMN | US$1.74M | US$4.99M | n/a | 5.5× | n/a | 0.5× | −28.1% | 0.9× | -0.10 |
| PRF Technologies Ltd. · NASDAQ:PRFX | US$1.66M | −US$9.82M | n/a | −249× | n/a | 0.1× | n/a | 0.0× | 1.93 |
| Jupiter Neurosciences, Inc. · NASDAQ:JUNS | US$1.63M | US$1.33M | n/a | 16.9× | n/a | n/a | n/a | n/a | 1.88 |
| Median of the others | US$1.82M | US$689,358 | 1.9× | 3.7× | 0.4× | −123.3% | 0.0× | 1.34 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.50 USD · Analysts' mean
- EPS, year to Dec 2025
- -4.45 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Avi Minkowitz | Chief Executive Officer and Chief Financial Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| KALA BIO (NASDAQ:KALA) Q2 2022 Earnings Call | Thu, Aug 11, 2022 · 8:00 AM ET | Replay |
| KALA BIO (NASDAQ:KALA) Q1 2022 Earnings Call | Mon, May 16, 2022 · 8:00 AM ET | Replay |
| KALA BIO (NASDAQ:KALA) Q4 2021 Earnings Call | Tue, Mar 29, 2022 · 8:00 AM ET | Replay |
| KALA BIO (NASDAQ:KALA) Q3 2021 Earnings Call | Mon, Nov 15, 2021 · 10:30 AM ET | Replay |
| KALA BIO (NASDAQ:KALA) Q2 2021 Earnings Call | Thu, Aug 05, 2021 · 8:00 AM ET | Replay |
| KALA BIO (NASDAQ:KALA) Q1 2021 Earnings Call | Wed, May 05, 2021 · 8:00 AM ET | Replay |
| KALA BIO (NASDAQ:KALA) Q3 2020 Earnings Call | Thu, Nov 05, 2020 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 18, 2026 | −21.1% |
| Q2 2026 | Aug 19, 2026 | −6.5% |
| Q1 2026 | May 29, 2026 | −3.9% |
| Q3 2025 | Nov 19, 2025 · Before open | −8.1% |
| Q2 2025 | Aug 8, 2025 · Before open | +3.1% |
| Q1 2025 | May 14, 2025 · After close | −1.5% |
| Q4 2024 | Mar 27, 2025 · Before open | −3.8% |
| Q3 2024 | Nov 12, 2024 · After close | −2.0% |
| Q2 2024 | Aug 6, 2024 · After close | −0.8% |
| Q1 2024 | May 14, 2024 · After close | −1.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 29, 2024 · Before open | +0.3% |
| Q3 2023 | Nov 13, 2023 · Before open | −0.7% |
| Q2 2023 | Aug 4, 2023 · Before open | −1.6% |
| Q1 2023 | May 9, 2023 · Before open | −2.5% |
| Q4 2022 | Mar 3, 2023 · Before open | +64.7% |
| Q3 2022 | Nov 8, 2022 · Before open | +0.8% |
| Q2 2022 | Aug 11, 2022 · Before open | −5.8% |
| Q1 2022 | May 16, 2022 · Before open | +8.5% |
| Q4 2021 | Mar 29, 2022 · Before open | −14.3% |
| Q3 2021 | Nov 15, 2021 · Before open | +1.4% |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock (or pre-funded warrants in lieu thereof) Closed: US$10M raised · US$1 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Repay certain indebtedness and general corporate purposes | Dec 5, 2025 |
| Private placement of non-voting convertible preferred stock Tranche closed: US$1.8M raised Buyers: David E. Lazar ($6 million of non-voting convertible preferred stock; $1.8 million of Series AA preferred in first closing, $4.2 million of Series AAA preferred in second closing) Insiders: Investor David E. Lazar was appointed Chief Executive Officer and Chairman of the Board effective immediately. Use of proceeds: Evaluation and redevelopment of product candidates and patent portfolio, working capital and funding for a potential strategic transaction | Dec 1, 2025 |
| Private placement of common stock and Series I Convertible Non-Redeemable Preferred Stock Announced: about US$10.75M · US$6.44 a share Buyers: SR One; Cormorant Asset Management; Woodline Partners Use of proceeds: Advance clinical development of KPI-012 for persistent corneal epithelial defect and general corporate purposes | Dec 30, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Kala Pharmaceuticals, Inc. Priced at US$15.00 a share on Jul 19, 2017.
- Price
- US$15.00 a share
- Shares offered
- 6,000,000 shares of common stock
- Offering size
- US$90 million
- Underwriters' option
- Up to 900,000 more shares
- Listing
- KALA on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, BofA Merrill Lynch, Wells Fargo Securities, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Jul 25, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 21, 2015 |
| Filed publicly | Jun 23, 2017 |
| Amended once | Jul 10, 2017 |
| Shares registered with an exchange | Jul 14, 2017 |
| Declared effective by the SEC | Jul 19, 2017 |
| Final prospectus, with the price | Jul 20, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 20, 2017 |
| EFFECT · Notice that a registration is effective | Jul 19, 2017 |
| CORRESP · Letter to the SEC | Jul 17, 2017 |
| CORRESP · Letter to the SEC | Jul 17, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 14, 2017 |
| S-1/A · Registration statement, amended | Jul 10, 2017 |
| CORRESP · Letter to the SEC | Jun 28, 2017 |
| CORRESP · Letter to the SEC | Jun 23, 2017 |
| S-1 · Registration statement | Jun 23, 2017 |
| UPLOAD · Letter from the SEC | Jun 14, 2017 |
All 19 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Jun 2, 2017 |
| DRS/A · Draft registration statement, amended | Jun 2, 2017 |
| UPLOAD · Letter from the SEC | Apr 26, 2017 |
| DRS/A · Draft registration statement, amended | Mar 30, 2017 |
| DRS/A · Draft registration statement, amended | Feb 4, 2016 |
| DRSLTR · Letter to the SEC with a draft | Nov 3, 2015 |
| DRS/A · Draft registration statement, amended | Nov 3, 2015 |
| UPLOAD · Letter from the SEC | Oct 20, 2015 |
| DRS · Draft registration statement | Sep 21, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 20, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 3.89M | 11.2M | 6.36M | 6.07M | 0 | 0 | 0 |
| Cost of revenue | 317.0K | 259.0K | 303.0K | 2.56M | 4.10M | 3.17M | 2.85M | 955.0K | 643.0K | 297.0K |
| Gross profit | -317.0K | -259.0K | -303.0K | 1.33M | 7.14M | 3.19M | 3.23M | -955.0K | -643.0K | -297.0K |
| Research and development | 18.8M | 22.1M | 18.6M | 17.7M | 11.5M | 18.4M | 27.3M | 29.3M | 29.0M | 25.0M |
| Selling, general and administrative | 23.6M | 18.3M | 20.6M | 65.0M | 105.1M | 81.1M | 65.0M | 35.4M | 10.9M | 7.64M |
| Operating income | -39.2M | -41.0M | -39.7M | -81.7M | -130.2M | -96.2M | -88.2M | -64.7M | -39.9M | -32.7M |
| Depreciation and amortization | 317.0K | 259.0K | 303.0K | 537.0K | 975.0K | 912.0K | 843.0K | 352.0K | 287.0K | 297.0K |
| EBITDA | -38.8M | -40.7M | -39.4M | -81.2M | -129.3M | -95.3M | -87.4M | -64.4M | -39.6M | -32.4M |
| Interest expense | 3.28M | 5.78M | 5.81M | 7.27M | 8.38M | 8.59M | 8.48M | 3.31M | 1.02M | 767.0K |
| Income before tax | -27.0M | -38.5M | -42.2M | -44.8M | -142.6M | -104.3M | -94.3M | -66.7M | -42.2M | -33.2M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -27.0M | -38.5M | -42.2M | -44.8M | -142.6M | -104.3M | -94.3M | -66.7M | -42.2M | -33.2M |
| Earnings per share, basic | -3.31 | -10.15 | -17.35 | -29.48 | -108.32 | -1.99 | -2.76 | -2.49 | -3.71 | -28.07 |
| Earnings per share, diluted | -3.31 | -10.15 | -17.35 | -29.48 | -108.32 | -1.99 | -2.76 | -2.49 | -3.71 | -28.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.56M | 51.2M | 50.9M | 70.5M | 92.1M | 77.3M | 85.4M | 170.9M | 114.6M | 45.5M |
| Short-term investments | 0 | 76.3M | 699.0K | 0 | ||||||
| Receivables | 236.0K | 195.0K | 15.3M | 9.60M | 11.6M | 1.03M | ||||
| Inventory | 7.67M | 8.64M | 5.23M | 4.65M | 4.09M | 0 | ||||
| Current assets | 9.49M | 52.8M | 52.9M | 85.9M | 124.4M | 171.4M | 105.5M | 177.0M | 115.2M | 45.6M |
| Property, plant and equipment | 749.0K | 753.0K | 400.0K | 2.72M | 3.17M | 2.70M | 2.17M | 786.0K | 594.0K | |
| Goodwill | 0 | |||||||||
| Total assets | 9.49M | 55.5M | 55.9M | 86.8M | 139.4M | 221.6M | 154.3M | 221.0M | 116.5M | 46.3M |
| Accounts payable | 986.0K | 628.0K | 919.0K | 2.83M | 4.90M | 1.72M | 2.52M | 5.45M | 1.20M | 997.0K |
| Current liabilities | 2.49M | 17.0M | 8.35M | 25.7M | 37.4M | 22.2M | 24.8M | 17.0M | 14.9M | 5.55M |
| Long-term debt | 20.1M | 34.2M | 37.9M | 78.9M | 72.2M | 71.2M | 70.2M | 12.0M | 9.10M | |
| Total debt | 29.3M | 34.0M | 43.3M | 80.0M | 75.0M | 75.0M | 75.0M | 18.9M | 9.65M | |
| Total liabilities | 2.49M | 43.2M | 48.4M | 67.8M | 122.6M | 121.6M | 124.6M | 116.0M | 26.9M | 15.7M |
| Shareholders' equity | 7.00M | 12.3M | 7.50M | 19.0M | 16.8M | 100.0M | 29.7M | 105.0M | 89.7M | -87.8M |
| Shares outstanding | 557.0K | 6.09M | 2.76M | 1.71M | 1.32M | 58.9M | 36.1M | 33.9M | 24.5M | 1.18M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -32.0M | -29.4M | -27.9M | -78.9M | -108.2M | -90.7M | -92.7M | -54.1M | -34.1M | -27.3M |
| Capital spending | -15.0K | -208.0K | -610.0K | -313.0K | -886.0K | -1.94M | -1.33M | -1.58M | -480.0K | -153.0K |
| Free cash flow | -32.0M | -29.6M | -28.5M | -79.2M | -109.1M | -92.6M | -94.1M | -55.7M | -34.6M | -27.5M |
| Cash from investing | -15.0K | -208.0K | -429.0K | 62.7M | 70.8M | -78.2M | -1.33M | -1.58M | -480.0K | -153.0K |
| Cash from financing | -11.6M | 29.9M | 8.51M | -7.94M | 42.6M | 160.6M | 8.98M | 124.1M | 103.7M | 67.2M |
| Dividends paid | -365.0K | 0 | ||||||||
| Share buybacks | 365.0K | 1.58M | 160.7M | 9.01M | 71.3M | 97.1M | 67.9M | |||
| Change in cash | -43.6M | 286.0K | -19.9M | -24.1M | 5.12M | -8.28M | -85.1M | 68.4M | 69.1M | 39.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| NT 10-Q · Late filing notice | Nov 13, 2026 | Explanation request | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 8-K · Current report | Nov 3, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 19, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Sep 24, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 11, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 10, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 28, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 19, 2026 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2026 | Explanation request | SEC |
| 8-K · Current report | Jul 22, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jul 22, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 2, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jun 26, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jun 12, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| S-3 · Registration statement | May 7, 2026 | Offer document | SEC |
| 8-K · Current report | May 7, 2026 | Current report | SEC |
| 10-K · Annual report | Apr 15, 2026 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2026 | Explanation request | SEC |
| D | Mar 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 4, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 20, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Feb 18, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Feb 17, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Feb 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 13, 2026 | Other filings | SEC |
| D | Feb 12, 2026 | Other filings | SEC |
| S-3 · Registration statement | Feb 9, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Feb 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2026 | Management or board change | SEC |
| 8-K · Current report | Feb 2, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Jan 26, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 23, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Jan 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 6, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 2, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Dec 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 29, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| PRER14A | Dec 19, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 16, 2025 | Current report | SEC |
| 8-K · Current report | Dec 16, 2025 | Current report | SEC |
| 8-K · Current report | Dec 5, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 5, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Dec 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 3, 2025 | Big-stake notice | SEC |
| 3/A · Initial statement of ownership, amended | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 19, 2025 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2025 | Explanation request | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 8-K · Current report | Nov 10, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 22, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 20, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 3, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Oct 2, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 1, 2025 | Current report | SEC |
| 8-K · Current report | Sep 29, 2025 | Current report | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 11, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 11, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 2, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 8-K · Current report | Jul 9, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 11, 2025 | Management or board change | SEC |
| 424B5 · Prospectus | Mar 31, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Feb 5, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Feb 4, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 31, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 31, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jan 24, 2025 | Offer document | SEC |
| 4/A · Change in ownership, amended | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 3, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 31, 2024 | Big-stake notice | SEC |
| D | Dec 31, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Sep 25, 2024 | Management or board change | SEC |
| 424B5 · Prospectus | Sep 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | Aug 1, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jul 31, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 29, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 26, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 25, 2024 | Offer document | SEC |
| 144 · Notice of proposed sale | Jul 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 16, 2024 | Other filings | SEC |
| SC 13D · Big-stake notice | Jul 8, 2024 | Big-stake notice | SEC |
| D | Jun 28, 2024 | Other filings | SEC |
| SC 13D · Big-stake notice | Jun 28, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2024 | Material contract | SEC |
| 144 · Notice of proposed sale | Jun 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 31, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | May 30, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
This page holds 200 of 679 filings. Open Filings
Cap table
Built by 6ix from Kala Bio, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 644,660
- Fully diluted
- 644,660
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 644,660 | Nov 16, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 16, 2026 | 644,660 |
| Nov 16, 2026 | |
| Nov 12, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Kolchinsky Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Wave Life Sciences Ltd. (Director · Since at least Aug 14, 2015); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past) | Director · Oct 3, 2018 – Mar 13, 2020 · Past |
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Jul 19, 2017 – Jun 17, 2021 · Past |
| David Lazar Other companies: Aterian, Inc. (Chair of the Board · Since at least Apr 27, 2026); Quantum Cyber N.V. (CEO · Since at least Feb 13, 2026); Sow Good Inc. (Chief Executive Officer and Chair of the Board · Since at least Dec 31, 2025); Indaptus Therapeutics, Inc. (Director · Since at least Dec 22, 2025); Stablecoin Development Corporation (Chief Executive Officer, Director · Since at least Aug 19, 2025); Bio Green Med Solution, Inc. (Interim CEO · Jan 2, 2025 – Feb 26, 2025 · Past); LQR House Inc. (President, Director · Oct 15, 2024 – Apr 2, 2025 · Past); CapForce Inc. (Chief Executive Officer, Director · Mar 25, 2024 – Jul 30, 2024 · Past); FiEE, Inc (Director · Dec 29, 2023 – Feb 18, 2025 · Past); Titan Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 24, 2023 – Jul 26, 2023 · Past) | Chief Executive Officer, Director · Since at least Nov 23, 2025 |
| Andrew Koven Other companies: MetaVia Inc. (Chairman of the Board · Since at least Jul 9, 2021); Aralez Pharmaceuticals Inc (President & Chief Business Off · Feb 5, 2016 – Jun 4, 2018 · Past); POZEN Inc (President, Chief Business Ofc. · May 31, 2015 – Jun 3, 2015 · Past); Auxilium Pharmaceuticals Inc (EVP, CAO, GC and Secretary · Feb 3, 2012 – Jan 29, 2015 · Past); Inspire Pharmaceuticals Inc (EVP & Chief Admin & Legal Ofc · May 10, 2010 – May 13, 2011 · Past); Sepracor Inc (Exec VP, General Counsel · Mar 1, 2007 – Oct 20, 2009 · Past); Kos Pharmaceuticals Inc (EVP, General Counsel · Jan 26, 2006 – Dec 13, 2006 · Past) | Director · Since at least Sep 28, 2017 |
| Mark Iwicki Other companies: Inhibikase Therapeutics, Inc. (Chief Executive Officer - Inhibikase · Since at least Feb 14, 2025); Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Third Harmonic Bio Inc. (Director · Since at least Sep 14, 2022); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Jade Biosciences, Inc. (Director · Apr 2, 2021 – Jun 5, 2024 · Past); Pulmatrix, Inc. (Director · Mar 20, 2017 – Jan 28, 2021 · Past); Aimmune Therapeutics Inc (Director · May 25, 2016 – Oct 10, 2020 · Past) | Director · Since at least Jul 19, 2017 |
| Robert Langer Other companies: Seer, Inc. (Director · Since at least Dec 3, 2020); Lyra Therapeutics, Inc. (David H. Koch Institute Professor, Massachusetts Institute of Technology · Since at least Apr 30, 2020); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Moderna, Inc. (Director · Dec 7, 2018 – May 6, 2024 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – Oct 14, 2019 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 21, 2016 · Past); Ocata Therapeutics Inc (Director · Oct 4, 2011 – Feb 10, 2016 · Past) | Director · Jul 19, 2017 – Jun 12, 2018 · Past |
| Gregory D Perry Other companies: Novelion Therapeutics Inc (See Remarks · Nov 29, 2016 – May 9, 2017 · Past); Aegerion Pharmaceuticals Inc (See Remarks · Jul 6, 2015 – May 9, 2016 · Past); Eleven Biotherapeutics Inc (Chief Financial and Business · Feb 5, 2014 – Feb 26, 2015 · Past); InVivo Therapeutics Holdings Corp (Interim CFO · Sep 30, 2013 – Dec 30, 2013 · Past); Ocata Therapeutics Inc (Director · Dec 2, 2011 – Feb 10, 2016 · Past); ImmunoGen Inc (Chief Financial Officer · Jan 9, 2009 – Sep 10, 2013 · Past) | Director · Since at least Feb 28, 2018 |
| Robert I Tepper Other companies: Constellation Pharmaceuticals Inc (Director · Jul 18, 2018 – Jun 6, 2019 · Past); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Jun 5, 2019 · Past); Jounce Therapeutics Inc (Director · Jan 26, 2017 – Jun 26, 2020 · Past); Dare Bioscience, Inc. (Director · Apr 10, 2014 – Jun 26, 2015 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Feb 3, 2015 · Past); Millennium Pharmaceuticals Inc (President, R&D · Sep 15, 2005 – Feb 12, 2007 · Past) | Director · Jul 19, 2017 – Jul 25, 2017 · Past |
| Mark Blumenkranz Other companies: Annexon, Inc. (BOARD MEMBER · Since at least Aug 10, 2026); IVERIC bio Inc (Director · Jul 15, 2020 – Jul 11, 2023 · Past); 1Life Healthcare Inc (Director · Jan 30, 2020 – Feb 22, 2023 · Past); Presbia PLC (Director · Jan 28, 2015 – Mar 16, 2015 · Past); Adverum Biotechnologies Inc (Director · Jul 30, 2014 – Feb 12, 2016 · Past) | Director · Nov 15, 2021 – Jun 11, 2024 · Past |
| Eric Trachtenberg Other companies: Aralez Pharmaceuticals Inc (GC, CCO & Secretary · Feb 5, 2016 – Mar 19, 2018 · Past); POZEN Inc (Deputy General Counsel · Jun 22, 2015 – Jun 22, 2015 · Past) | SEE REMARKS · Apr 2, 2018 – Jan 4, 2024 · Past |
All 29 people
| Person | Seat |
|---|---|
| Howard B Rosen Other companies: Talphera, Inc. (Director · Feb 10, 2011 – Oct 10, 2023 · Past); Pharsight Corp (Director · Oct 31, 2008 – Oct 31, 2008 · Past) | Director · Since at least Jul 19, 2017 |
| Paulina Hill Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Neuronetics, Inc. (Director · Jun 27, 2018 – Jul 2, 2018 · Past) | Director · Jul 19, 2017 – Jun 12, 2018 · Past |
| Todd Bazemore Other companies: Pulmatrix, Inc. (Chief Operating Officer · Since at least Oct 1, 2020); Dyax Corp (EVP & Chief Commercial Officer · Apr 16, 2014 – Jan 22, 2016 · Past) | Director · Since at least Nov 20, 2017 |
| C Daniel Myers Other companies: Alimera Sciences Inc (Director · Apr 21, 2010 – Jan 4, 2023 · Past) | Director · Since at least Oct 15, 2021 |
| Chaim D Berger Other companies: Nova Minerals Corp (Director · Since at least Mar 17, 2026) | Director · Since at least Jan 30, 2026 |
| Charles Douglas McDermott Other companies: Equillium, Inc. (Director · Since at least Oct 11, 2018) | President and Chief Bus. Off. · Jul 19, 2017 – Jul 19, 2017 · Past |
| Gregory Grunberg Other companies: 89bio Inc (Director · Nov 8, 2019 – Feb 9, 2023 · Past) | Director · Jul 19, 2017 – Jun 17, 2021 · Past |
| Romulus K Brazzell Other companies: Inspire Pharmaceuticals Inc (EVP, Medical & Scientific · Jan 19, 2006 – May 13, 2011 · Past) | SEE REMARKS · Since at least Jul 19, 2017 |
| Avi Minkowitz | Chief Executive Officer and Chief Financial Officer · Since at least Sep 29, 2026 |
| Avraham Minkowitz | Chief Executive Officer, Director · Since at least Jan 30, 2026 |
| Brendan P Purdy | Director · Since at least Jan 30, 2026 |
| Darius Kharabi | CHIEF BUSINESS OFFICER · Since at least Nov 15, 2021 |
| Hillel D Posen | Director · Since at least Jan 30, 2026 |
| Hongming Chen | CHIEF SCIENTIFIC OFFICER · Feb 7, 2018 – Oct 26, 2021 · Past |
| Marjan Farid | Director · Since at least Oct 31, 2022 |
| Mary Reumuth | CHIEF FINANCIAL OFFICER · Since at least Jul 19, 2017 |
| Michele LaRussa | Sr. VP, Regulatory and Quality · Jul 19, 2017 – Feb 7, 2018 · Past |
| Robert Bradley Paull | Director · Jul 19, 2017 – Jun 16, 2022 · Past |
| Yonatan C Colman | Director · Since at least Jan 30, 2026 |
Log in to ask 6ix AI your own questions about Kala Bio, Inc.